middle.news
Alterity Therapeutics Secures US Patent Extending ATH434 Protection to 2045
8:36am on Wednesday 12th of August, 2026 AEST
•
Biotechnology
Read Story
Alterity Therapeutics Secures US Patent Extending ATH434 Protection to 2045
8:36am on Wednesday 12th of August, 2026 AEST
Key Points
New US patent covers crystalline mesylate form of ATH434
Patent extends protection to at least 2045
Strengthens IP ahead of Phase 3 trial initiation in MSA
Enables future ATH434 development for Parkinson’s disease
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE